摘要
目的 观察应用雷贝拉唑和血凝酶联合治疗消化性溃疡伴出血的有效性。方法 从2021年01月01日-2021年12月31日抽选诊治的50例消化性溃疡伴出血患者进行分析,用随机抽签法将其分成两组,各25例。比对组接受雷贝拉唑单独治疗,探究组接受雷贝拉唑和血凝酶联合治疗,比较两组间治疗效果、临床症状评分及不良反应发生情况。结果 探究组治疗总有效率较比对组更高,探究组治疗后的不良反应发生率较比对组更低,且探究组治疗后呕血、黑便、乏力症状评分均低于比对组,两组对比P<0.05,有统计学意义。结论 应用雷贝拉唑和血凝酶联合治疗消化性溃疡伴出血能让患者的治疗有效率得到明显提升,改善患者临床症状,降低患者不良反应的发生率。
Objective To observe the efficacy of rabeprazole combined with hemocoagulase in the treatment of peptic ulcer with bleeding. Methods From 2021-01-01 to 2021-12-31, 50 patients with peptic ulcer with bleeding who were diagnosed and treated in our hospital were selected for analysis, and they were divided into two groups by random drawing, 25 cases in each. The reference group received rabeprazole alone, and the study group received combined rabeprazole and hemagglutinin therapy. The therapeutic effects, clinical symptom scores and adverse reactions were compared between the groups. Results The total treatment effective rate of the exploration group was higher than that of the comparison group, the incidence of adverse reactions in the exploration group after treatment was lower than that of the comparison group, and the symptom scores of hematemesis, melena, and fatigue in the exploration group after treatment were lower than those in the comparison group. Group comparison P<0.05, there is statistical significance. Conclusions The combination of rabeprazole and hemocoagulase in the treatment of peptic ulcer with bleeding can significantly improve the treatment efficiency of patients, improve the clinical symptoms of patients, and reduce the incidence of adverse reactions in patients, which is worthy of reference.
作者
孙雪丹
SUN Xuedan(Harbin 242 Hospital,Harbin 150066,China)
出处
《航空航天医学杂志》
2022年第6期648-650,共3页
Journal of Aerospace medicine
关键词
消化性溃疡
出血
雷贝拉唑
血凝酶
疗效
Peptic ulcer
Bleeding
Rabeprazole
Hemagglutinin
Efficacy
